Search
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. … Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein.
Interferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalIt has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Oxitriptan
go.drugbank.com/drugs/DB02959ApprovedInvestigationalNutraceuticalWithdrawnthe United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication … 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in
H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalIt offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749 … H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].
Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-CarboxylateEtranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44161] It is additionally notable for its cost per treatment - approximately 3.5 million USD - earning it the title of most expensive drug in the world. … [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801]
Sulfathiazole
go.drugbank.com/drugs/DB06147ApprovedVet approvedWithdrawnIt used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP
Pentastarch
go.drugbank.com/drugs/DB09111ApprovedWithdrawnIt is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically … [L14867] It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir